GSK Licenses Linerixibat to Alfasigma in Deal Worth Up to USD 690 Million
Bengaluru: GSK said on Monday it will receive up to USD 690 million from Italian pharmaceutical company Alfasigma for the worldwide rights to linerixibat, an experimental treatment for severe itching in patients with a rare liver disease.
The drug treats cholestatic pruritus, a relentless internal itch affecting patients with primary biliary cholangitis (PBC), an autoimmune disease where the body's immune system attacks bile ducts in the liver.
Alfasigma will pay GSK $300 million upfront plus another $100 million upon expected U.S. approval by March 24. It will pay $20 million when European and UK regulators approve the drug.
GSK is also eligible for up to $270 million in sales milestones and will earn tiered double-digit royalties on worldwide sales from Alfasigma, which already markets treatments for liver diseases across more than 100 countries.
